TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect Evaluation of a Theory and Evidence Based Programme for Establishing Effective Breastfeeding After Short Time Hospitalization Post Partum
Brief Summary: The purpose of this study is to evaluate if the developed theory and evidence based programme has a positive effect on mother's breastfeeding self efficacy, establishing an effective breastfeeding and breastfeeding duration after short time hospitalization.


Options:
A: Arm Label: New breastfeeding programme; Type: EXPERIMENTAL; Interventions: Other: New Breastfeeding Counselling | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: OTHER; Name: New Breastfeeding Counselling; Assigned to Arm(s): New breastfeeding programme | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual
B: Arm Label: 3-week visit; Type: EXPERIMENTAL; Interventions: Other: 3-week visit | Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: OTHER; Name: 3-week visit; Assigned to Arm(s): 3-week visit | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): usual care
C: Arm Label: Cognitive Behavioral Therapy Intervention for Anxiety; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy Intervention for Anxiety | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy Intervention for Anxiety; Assigned to Arm(s): Cognitive Behavioral Therapy Intervention for Anxiety
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: RLPT | Intervention Type: BEHAVIORAL; Name: RLPT; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Clinical Trial of Bupropion SR and Individual Smoking Cessation Counseling
Brief Summary: The purpose of this study was to determine if bupropion plus counseling was more effective than bupropion alone or counseling alone in helping smokers quit smoking.


Options:
A: Arm Label: Active bupropion + counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion + counseling | Arm Label: Active bupropion , No counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion, No counseling | Arm Label: Placebo medication + counseling; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo medication + counseling | Arm Label: Placebo medication, No counseling; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo medication, No counseling | Intervention Type: DRUG; Name: Active bupropion + counseling; Assigned to Arm(s): Active bupropion + counseling | Intervention Type: DRUG; Name: Active bupropion, No counseling; Assigned to Arm(s): Active bupropion , No counseling | Intervention Type: DRUG; Name: Placebo medication + counseling; Assigned to Arm(s): Placebo medication + counseling | Intervention Type: DRUG; Name: Placebo medication, No counseling; Assigned to Arm(s): Placebo medication, No counseling
B: Arm Label: Gain Framed Absitnence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Arm Label: Loss Framed Abstinence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program | Intervention Type: BEHAVIORAL; Name: Smoking Abstinence Program; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Clinical Trial of Bupropion SR and Individual Smoking Cessation Counseling
Brief Summary: The purpose of this study was to determine if bupropion plus counseling was more effective than bupropion alone or counseling alone in helping smokers quit smoking.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selegiline + nicotine replacement therapy | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo + nicotine replacement therapy | Intervention Type: DRUG; Name: Selegiline + nicotine replacement therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo + nicotine replacement therapy; Assigned to Arm(s): 2
B: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pil; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Sugar Pil
D: Arm Label: Active bupropion + counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion + counseling | Arm Label: Active bupropion , No counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion, No counseling | Arm Label: Placebo medication + counseling; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo medication + counseling | Arm Label: Placebo medication, No counseling; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo medication, No counseling | Intervention Type: DRUG; Name: Active bupropion + counseling; Assigned to Arm(s): Active bupropion + counseling | Intervention Type: DRUG; Name: Active bupropion, No counseling; Assigned to Arm(s): Active bupropion , No counseling | Intervention Type: DRUG; Name: Placebo medication + counseling; Assigned to Arm(s): Placebo medication + counseling | Intervention Type: DRUG; Name: Placebo medication, No counseling; Assigned to Arm(s): Placebo medication, No counseling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Clinical Trial of Bupropion SR and Individual Smoking Cessation Counseling
Brief Summary: The purpose of this study was to determine if bupropion plus counseling was more effective than bupropion alone or counseling alone in helping smokers quit smoking.


Options:
A: Arm Label: Active bupropion + counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion + counseling | Arm Label: Active bupropion , No counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion, No counseling | Arm Label: Placebo medication + counseling; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo medication + counseling | Arm Label: Placebo medication, No counseling; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo medication, No counseling | Intervention Type: DRUG; Name: Active bupropion + counseling; Assigned to Arm(s): Active bupropion + counseling | Intervention Type: DRUG; Name: Active bupropion, No counseling; Assigned to Arm(s): Active bupropion , No counseling | Intervention Type: DRUG; Name: Placebo medication + counseling; Assigned to Arm(s): Placebo medication + counseling | Intervention Type: DRUG; Name: Placebo medication, No counseling; Assigned to Arm(s): Placebo medication, No counseling
B: Arm Label: Drug Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: matching placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Drug Selegiline | Intervention Type: OTHER; Name: matching placebo; Assigned to Arm(s): Matching placebo
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Gain Framed Absitnence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Arm Label: Loss Framed Abstinence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program | Intervention Type: BEHAVIORAL; Name: Smoking Abstinence Program; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Bupropion Alone and in Combination With Nicotine Gum
Brief Summary: Focus of this study was to determine if bupropion was more effective for smoking cessation when used alone or combined with nicotine gum.


Options:
A: Arm Label: Active bupropion-Active gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + nicotine gum | Arm Label: Active bupropion-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion-Placebo gum | Arm Label: Placebo medication-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo bupropion-Placebo gum | Intervention Type: DRUG; Name: bupropion + nicotine gum; Assigned to Arm(s): Active bupropion-Active gum | Intervention Type: DRUG; Name: Active bupropion-Placebo gum; Assigned to Arm(s): Active bupropion-Placebo gum | Intervention Type: DRUG; Name: Placebo bupropion-Placebo gum; Assigned to Arm(s): Placebo medication-Placebo gum
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Bupropion Alone and in Combination With Nicotine Gum
Brief Summary: Focus of this study was to determine if bupropion was more effective for smoking cessation when used alone or combined with nicotine gum.


Options:
A: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A
C: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban
D: Arm Label: Active bupropion-Active gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + nicotine gum | Arm Label: Active bupropion-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion-Placebo gum | Arm Label: Placebo medication-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo bupropion-Placebo gum | Intervention Type: DRUG; Name: bupropion + nicotine gum; Assigned to Arm(s): Active bupropion-Active gum | Intervention Type: DRUG; Name: Active bupropion-Placebo gum; Assigned to Arm(s): Active bupropion-Placebo gum | Intervention Type: DRUG; Name: Placebo bupropion-Placebo gum; Assigned to Arm(s): Placebo medication-Placebo gum

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Bupropion Alone and in Combination With Nicotine Gum
Brief Summary: Focus of this study was to determine if bupropion was more effective for smoking cessation when used alone or combined with nicotine gum.


Options:
A: Arm Label: 1: Bup+MM; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Medication Management, Drug: placebo patch | Arm Label: 2 Bup+Mayo; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Mayo Counseling, Drug: placebo patch | Arm Label: 3 Patch+MM; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal system, Behavioral: Medication Management, Drug: placebo bupropion | Arm Label: 4 Patch+Mayo; Type: EXPERIMENTAL; Interventions: Drug: nicotine transdermal system, Behavioral: Mayo Counseling, Drug: placebo bupropion | Intervention Type: DRUG; Name: nicotine transdermal system; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: BEHAVIORAL; Name: Medication Management; Assigned to Arm(s): 1: Bup+MM, 3 Patch+MM | Intervention Type: BEHAVIORAL; Name: Mayo Counseling; Assigned to Arm(s): 2 Bup+Mayo, 4 Patch+Mayo | Intervention Type: DRUG; Name: placebo patch; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: DRUG; Name: placebo bupropion; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: SSR591813L (dianicline); Assigned to Arm(s): N/A
D: Arm Label: Active bupropion-Active gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + nicotine gum | Arm Label: Active bupropion-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion-Placebo gum | Arm Label: Placebo medication-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo bupropion-Placebo gum | Intervention Type: DRUG; Name: bupropion + nicotine gum; Assigned to Arm(s): Active bupropion-Active gum | Intervention Type: DRUG; Name: Active bupropion-Placebo gum; Assigned to Arm(s): Active bupropion-Placebo gum | Intervention Type: DRUG; Name: Placebo bupropion-Placebo gum; Assigned to Arm(s): Placebo medication-Placebo gum

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Linoleic Acid for Secondary Prevention of Coronary Heart Disease and Death in the Sydney Heart Study: a Randomized Controlled Dietary Trial
Brief Summary: The substitution of polyunsaturated fatty acids (PUFA) for saturated fatty acids (SFA) is a cornerstone of worldwide dietary advice for coronary heart disease (CHD) risk reduction. However, clinical CHD benefits specific to the omega-6 PUFA linoleic acid (LA), and distinct from omega-3 PUFAs, have not been established. The Sydney Diet-Heart Study (SDHS; 1966-1973) was a randomized controlled secondary CHD prevention trial testing whether selectively increasing omega-6 LA from safflower oil in place of SFA reduced CHD and improved survival. A full analysis of mortality outcomes has not been published. The investigators recovered the original SDHS dataset, which included detailed longitudinal dietary, smoking and coded mortality data, permitting evaluation of smoking relapse rates, and all-cause, CVD and CHD mortality outcomes by nutrient intake and duration of diet exposure. Data recovery also permitted the first complete meta-analysis of LA intervention trials on mortality outcomes.

Objectives are (1) to evaluate whether increasing dietary linoleic acid alters CVD and CHD mortality, and (2) to assess whether changes in smoking relapse rates contribute to observed mortality differences.


Options:
A: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
B: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil
C: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Linoleic Acid for Secondary Prevention of Coronary Heart Disease and Death in the Sydney Heart Study: a Randomized Controlled Dietary Trial
Brief Summary: The substitution of polyunsaturated fatty acids (PUFA) for saturated fatty acids (SFA) is a cornerstone of worldwide dietary advice for coronary heart disease (CHD) risk reduction. However, clinical CHD benefits specific to the omega-6 PUFA linoleic acid (LA), and distinct from omega-3 PUFAs, have not been established. The Sydney Diet-Heart Study (SDHS; 1966-1973) was a randomized controlled secondary CHD prevention trial testing whether selectively increasing omega-6 LA from safflower oil in place of SFA reduced CHD and improved survival. A full analysis of mortality outcomes has not been published. The investigators recovered the original SDHS dataset, which included detailed longitudinal dietary, smoking and coded mortality data, permitting evaluation of smoking relapse rates, and all-cause, CVD and CHD mortality outcomes by nutrient intake and duration of diet exposure. Data recovery also permitted the first complete meta-analysis of LA intervention trials on mortality outcomes.

Objectives are (1) to evaluate whether increasing dietary linoleic acid alters CVD and CHD mortality, and (2) to assess whether changes in smoking relapse rates contribute to observed mortality differences.


Options:
A: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
B: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil
C: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
D: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group

Answer: B